In Vitro:Article Title: Tamandarin analogs and fragments thereof and methods of making and using
Article Snippet: .. TABLE 1 In vitro results of tamandarin B (units: Molar) DU145 LN-caP IGROV IGROV-ET SK-BR3 SK-MEl28 A549 GI50 7.08E−09 5.84E−09 7.31E−09 1.73E−07 5.44E−09 3.03E−09 7.62E−09 TGI 2.41E−08 2.13E−08 2.91E−08 2.04E−06 2.49E−08 1.19E−08 4.01E−08 LC50 7.97E−08 1.42E−07 1.33E−07 9.59E−06 2.36E−07 1.19E−07 7.66E−07 K562 PANC1 HT29 LOVO LOVO-DOX HFLA HELA APL GI50 8.47E−09 1.40E−08 6.32E−09 3.05E−08 1.25E−06 3.90E−09 5.97E−08 TGI 2.63E−08 5.69E−08 4.32E−08 1.61E−07 9.59E−06 1.76E−08 1.16E−06 LC50 7.82E−08 4.13E−07 9.59E−06 9.59E−06 9.59E−06 1.20E−07 9.59E−06 TABLE 2 In vitro results of Phe5 tamandarin B (units: Molar) DU145 LN-caP IGROV IGROV-ET SK-BR3 SK-MEl28 A549 GI50 2.37E−09 1.52E−09 2.49E−09 2.15E−07 6.58E−10 2.74E−09 4.56E−09 TGI 1.02E−08 8.32E−09 1.28E−08 7.88E−07 4.49E−09 1.88E−08 3.90E−08 LC50 2.68E−07 1.01E−07 1.24E−07 6.35E−06 3.12E−07 2.05E−07 9.35E−07 K562 PANC1 HT29 LOVO LOVO-DOX HELA HELA APL GI50 2.32E−08 3.81E−09 4.77E−09 2.61E−08 3.58E−07 1.17E−09 4.45E−08 TGI 9.88E−07 3.28E−08 7.89E−08 8.81E−08 1.97E−06 4.61E−09 4.23E−07 LC50 9.88E−06 9.88E−06 9.88E−06 5.22E−06 9.88E−06 5.55E−08 9.88E−06 Cell Lines Name N° ATCC Species Tissue Characteristics A549 CCL-185 human lung lung carcinoma “NSCL” SK-MEL-28 HTB-72 human melanoma malignant melanoma HT29 HTB-38 human colon colon adenocarcinoma LoVo CCL-229 human colon colon adenocarcinoma LoVo-Dox human colon colon adenocarcinoma (MDR) DU-145 HTB-81 human prostate prostate carcinoma, not androgen receptors LN-caP CRL-1740 human prostate prostate adenocarcinoma, with androgen receptors SK-BR3 HTB-30 human breast breast adenocarcinoma, Her2/neu+, (pleural effusion) IGROV human ovary ovary adenocarcinoma IGROV-ET human ovary ovary adenocarcinoma, characterized as ET-743 resistant cells HeLa CCL-2 human cervix cervix epitheloid carcinoma HeLa-APL CCL-3 human cervix cervix epitheloid carcinoma, characterized as aplidine resistant cells PANC1 CRL-1469 human pancreas pancreatic epitheloid carcinoma Inhibition of Cells Growth by Colorimetric Assay. ..
Inhibition:Article Title: Tamandarin analogs and fragments thereof and methods of making and using
Article Snippet: .. TABLE 1 In vitro results of tamandarin B (units: Molar) DU145 LN-caP IGROV IGROV-ET SK-BR3 SK-MEl28 A549 GI50 7.08E−09 5.84E−09 7.31E−09 1.73E−07 5.44E−09 3.03E−09 7.62E−09 TGI 2.41E−08 2.13E−08 2.91E−08 2.04E−06 2.49E−08 1.19E−08 4.01E−08 LC50 7.97E−08 1.42E−07 1.33E−07 9.59E−06 2.36E−07 1.19E−07 7.66E−07 K562 PANC1 HT29 LOVO LOVO-DOX HFLA HELA APL GI50 8.47E−09 1.40E−08 6.32E−09 3.05E−08 1.25E−06 3.90E−09 5.97E−08 TGI 2.63E−08 5.69E−08 4.32E−08 1.61E−07 9.59E−06 1.76E−08 1.16E−06 LC50 7.82E−08 4.13E−07 9.59E−06 9.59E−06 9.59E−06 1.20E−07 9.59E−06 TABLE 2 In vitro results of Phe5 tamandarin B (units: Molar) DU145 LN-caP IGROV IGROV-ET SK-BR3 SK-MEl28 A549 GI50 2.37E−09 1.52E−09 2.49E−09 2.15E−07 6.58E−10 2.74E−09 4.56E−09 TGI 1.02E−08 8.32E−09 1.28E−08 7.88E−07 4.49E−09 1.88E−08 3.90E−08 LC50 2.68E−07 1.01E−07 1.24E−07 6.35E−06 3.12E−07 2.05E−07 9.35E−07 K562 PANC1 HT29 LOVO LOVO-DOX HELA HELA APL GI50 2.32E−08 3.81E−09 4.77E−09 2.61E−08 3.58E−07 1.17E−09 4.45E−08 TGI 9.88E−07 3.28E−08 7.89E−08 8.81E−08 1.97E−06 4.61E−09 4.23E−07 LC50 9.88E−06 9.88E−06 9.88E−06 5.22E−06 9.88E−06 5.55E−08 9.88E−06 Cell Lines Name N° ATCC Species Tissue Characteristics A549 CCL-185 human lung lung carcinoma “NSCL” SK-MEL-28 HTB-72 human melanoma malignant melanoma HT29 HTB-38 human colon colon adenocarcinoma LoVo CCL-229 human colon colon adenocarcinoma LoVo-Dox human colon colon adenocarcinoma (MDR) DU-145 HTB-81 human prostate prostate carcinoma, not androgen receptors LN-caP CRL-1740 human prostate prostate adenocarcinoma, with androgen receptors SK-BR3 HTB-30 human breast breast adenocarcinoma, Her2/neu+, (pleural effusion) IGROV human ovary ovary adenocarcinoma IGROV-ET human ovary ovary adenocarcinoma, characterized as ET-743 resistant cells HeLa CCL-2 human cervix cervix epitheloid carcinoma HeLa-APL CCL-3 human cervix cervix epitheloid carcinoma, characterized as aplidine resistant cells PANC1 CRL-1469 human pancreas pancreatic epitheloid carcinoma Inhibition of Cells Growth by Colorimetric Assay. ..
Colorimetric Assay:Article Title: Tamandarin analogs and fragments thereof and methods of making and using
Article Snippet: .. TABLE 1 In vitro results of tamandarin B (units: Molar) DU145 LN-caP IGROV IGROV-ET SK-BR3 SK-MEl28 A549 GI50 7.08E−09 5.84E−09 7.31E−09 1.73E−07 5.44E−09 3.03E−09 7.62E−09 TGI 2.41E−08 2.13E−08 2.91E−08 2.04E−06 2.49E−08 1.19E−08 4.01E−08 LC50 7.97E−08 1.42E−07 1.33E−07 9.59E−06 2.36E−07 1.19E−07 7.66E−07 K562 PANC1 HT29 LOVO LOVO-DOX HFLA HELA APL GI50 8.47E−09 1.40E−08 6.32E−09 3.05E−08 1.25E−06 3.90E−09 5.97E−08 TGI 2.63E−08 5.69E−08 4.32E−08 1.61E−07 9.59E−06 1.76E−08 1.16E−06 LC50 7.82E−08 4.13E−07 9.59E−06 9.59E−06 9.59E−06 1.20E−07 9.59E−06 TABLE 2 In vitro results of Phe5 tamandarin B (units: Molar) DU145 LN-caP IGROV IGROV-ET SK-BR3 SK-MEl28 A549 GI50 2.37E−09 1.52E−09 2.49E−09 2.15E−07 6.58E−10 2.74E−09 4.56E−09 TGI 1.02E−08 8.32E−09 1.28E−08 7.88E−07 4.49E−09 1.88E−08 3.90E−08 LC50 2.68E−07 1.01E−07 1.24E−07 6.35E−06 3.12E−07 2.05E−07 9.35E−07 K562 PANC1 HT29 LOVO LOVO-DOX HELA HELA APL GI50 2.32E−08 3.81E−09 4.77E−09 2.61E−08 3.58E−07 1.17E−09 4.45E−08 TGI 9.88E−07 3.28E−08 7.89E−08 8.81E−08 1.97E−06 4.61E−09 4.23E−07 LC50 9.88E−06 9.88E−06 9.88E−06 5.22E−06 9.88E−06 5.55E−08 9.88E−06 Cell Lines Name N° ATCC Species Tissue Characteristics A549 CCL-185 human lung lung carcinoma “NSCL” SK-MEL-28 HTB-72 human melanoma malignant melanoma HT29 HTB-38 human colon colon adenocarcinoma LoVo CCL-229 human colon colon adenocarcinoma LoVo-Dox human colon colon adenocarcinoma (MDR) DU-145 HTB-81 human prostate prostate carcinoma, not androgen receptors LN-caP CRL-1740 human prostate prostate adenocarcinoma, with androgen receptors SK-BR3 HTB-30 human breast breast adenocarcinoma, Her2/neu+, (pleural effusion) IGROV human ovary ovary adenocarcinoma IGROV-ET human ovary ovary adenocarcinoma, characterized as ET-743 resistant cells HeLa CCL-2 human cervix cervix epitheloid carcinoma HeLa-APL CCL-3 human cervix cervix epitheloid carcinoma, characterized as aplidine resistant cells PANC1 CRL-1469 human pancreas pancreatic epitheloid carcinoma Inhibition of Cells Growth by Colorimetric Assay. ..
|
ATCC is a verified supplier 
ATCC manufactures this product 